Description

27,69,000 equity shares of Venmax Drugs And Pharmaceuticals Ltd listed on BSE with effect from December 30, 2025, issued on preferential basis pursuant to conversion of warrants.

Summary

BSE has announced the listing of 27,69,000 equity shares of Venmax Drugs And Pharmaceuticals Ltd (Scrip Code: 531015) effective December 30, 2025. These shares were issued to non-promoters on a preferential basis pursuant to conversion of warrants at Rs. 20/- per share (face value Rs. 10/- with premium of Rs. 10/-). The shares rank pari-passu with existing equity shares and are subject to lock-in until July 13, 2026.

Key Points

  • Total shares listed: 27,69,000 equity shares of Rs. 10/- each
  • Issued at Rs. 20/- per share (Rs. 10/- face value + Rs. 10/- premium)
  • Allotted to non-promoters on preferential basis pursuant to warrant conversion
  • Trading commences: December 30, 2025
  • ISIN: INE154G01022
  • Scrip Code: 531015
  • Shares rank pari-passu with existing equity shares
  • All shares under lock-in until July 13, 2026

Regulatory Changes

No regulatory changes announced. This is a standard listing notification for new securities.

Compliance Requirements

Trading members are informed to note the listing of these new securities for trading purposes. The lock-in restrictions must be observed until the specified date.

Important Dates

  • August 16, 2025: First allotment of 20,55,000 shares (Dist. Nos. 5238931-7293930)
  • August 30, 2025: Second allotment of 3,60,667 shares (Dist. Nos. 7293931-7654597)
  • September 16, 2025: Third allotment of 3,53,333 shares (Dist. Nos. 7654598-8007930)
  • December 30, 2025: Effective date for trading
  • July 13, 2026: Lock-in period expires

Impact Assessment

This is a routine corporate action with minimal market-wide impact. The listing adds 27,69,000 shares to the tradable securities of Venmax Drugs And Pharmaceuticals Ltd, though all shares remain locked-in until July 2026. The preferential allotment to non-promoters indicates capital raising activity. Impact is limited to the company’s shareholders and potential investors in this specific scrip.

Impact Justification

Routine listing of preferential shares for a small-cap company. Limited market-wide impact, relevant primarily to specific shareholders and the company.